New combo therapy aims to boost immunotherapy in Hard-to-Treat cancers
NCT ID NCT05605496
First seen Feb 11, 2026 · Last updated May 15, 2026 · Updated 16 times
Summary
This study tests whether adding a new drug called NP137 to standard immunotherapy can help control advanced solid tumors that are stable or not responding well. About 57 adults with various solid tumors will receive NP137 alongside their usual PD-1/PD-L1 blocker. The goal is to see if this combination can shrink tumors or stop them from growing further.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre Antoine Lacassagne
Nice, 06189, France
-
Centre Léon Bérard
Lyon, 69008, France
-
Institut Claudius Regaud (IUCT Oncopole)
Toulouse, 31059, France
-
Institut Curie
Paris, 75005, France
-
Institut de Cancérologie Strasbourg Europe (ICANS)
Strasbourg, 67033, France
Conditions
Explore the condition pages connected to this study.